Skip to content

Just another WordPress site

Monthly Archives: February 2017

Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Posted byJulianne TwiningFebruary 9, 2017February 6, 2020Posted inpress releaseLeave a comment on Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Search for:

Recent Posts

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
An Open Letter to Patients and Their Families from BridgeBio Pharma CEO Neil Kumar
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes
BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

Recent Comments

Archives

April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
June 2019
May 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
June 2018
May 2018
April 2018
March 2018
January 2018
November 2017
October 2017
September 2017
July 2017
April 2017
February 2017
January 2017
December 2016

Categories

investor
media
news
partner
press release
Uncategorized

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

bridgebiowp, Proudly powered by WordPress.